BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 2.8%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) shares were up 2.8% during trading on Wednesday . The stock traded as high as $4.79 and last traded at $4.74. Approximately 1,078,536 shares traded hands during trading, a decline of 67% from the average daily volume of 3,248,327 shares. The stock had previously closed at $4.61.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $13.29.

BioCryst Pharmaceuticals Trading Down 0.7 %

The company has a 50-day moving average price of $5.25 and a two-hundred day moving average price of $5.63. The stock has a market capitalization of $944.17 million, a P/E ratio of -3.88 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $93.40 million during the quarter, compared to analysts' expectations of $89.19 million. Research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Braidwell LP raised its position in shares of BioCryst Pharmaceuticals by 92.1% in the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company's stock worth $37,970,000 after acquiring an additional 2,571,100 shares in the last quarter. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company's stock worth $108,978,000 after purchasing an additional 302,270 shares in the last quarter. Jump Financial LLC boosted its stake in shares of BioCryst Pharmaceuticals by 371.5% in the 3rd quarter. Jump Financial LLC now owns 404,913 shares of the biotechnology company's stock worth $2,867,000 after buying an additional 319,037 shares during the last quarter. Deerfield Management Company L.P. Series C boosted its stake in shares of BioCryst Pharmaceuticals by 148.6% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company's stock worth $23,265,000 after buying an additional 1,964,000 shares during the last quarter. Finally, Rice Hall James & Associates LLC boosted its stake in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,275,638 shares of the biotechnology company's stock worth $16,112,000 after buying an additional 402,674 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.